Continuous therapy management via smartphone

Press Releases Ypsomed Group

Burgdorf – Ypsomed has expanded the range of features of the mylife YpsoPump insulin pump system. New - the app-based integration of the Dexcom G6 Continuous Glucose Monitoring (CGM) System enables people with diabetes to continuously manage their therapy via their smartphone. Users of the mylife YpsoPump receive the advanced function of the pump system – called “mylife Assist” – via an update to the mylife App. The first countries launching mylife Assist are Germany, Switzerland, Austria and Denmark, with further countries following soon.

Témata:
Innovation & Digital Health

Čtěte více …

Ypsomed expands its options

Press Releases Ypsomed Group

Burgdorf – The Annual General Meeting of the Ypsomed Group on 30 June 2021 approved all proposals of the Board of Directors. The AGM elected Ms Betül Susamis Unaran as a new member of the Board of Directors and authorised the Board to increase the share capital.

Témata:
Management

Čtěte více …

Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

Alliance to Zero founded to achieve net zero emissions across the pharmaceutical supply chain

Press Releases Ypsomed Group

Burgdorf – Today, eight companies representing the pharmaceutical supply chain for pharma products announced the founding of the Alliance to Zero, a non-profit membership association for pharma and biotech supply chain companies that aims to facilitate the transition of the pharma sector to compliance with net zero emissions in line with the goals of the Paris Climate Agreement.

Témata:
Responsibility & Engagement

Čtěte více …

Ypsomed reaches agreement in legal dispute with Insulet

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) has reached an agreement in its legal dispute with Insulet Corp. (NASDAQ: PODD). Insulet acknowledges the contractually agreed fee and compensates Ypsomed for the termination of the cooperation with an additional USD 36.15 million. The total compensation thus amounts to USD 41.25 million. At the same time, Insulet drops its counterclaim of USD 18.7 million.

Čtěte více …

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Press Releases Ypsomed Group

Burgdorf / Indianapolis – Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Čtěte více …